Climb Bio (CLYM) Assets Average (2021 - 2026)
Climb Bio's (CLYM) quarterly Assets Average came in at $160.1 million in Q1 2026, down 23.4% YoY from $209.0 million in Q1 2025, and down 8.55% on a QoQ basis from $175.0 million in Q4 2025.
Climb Bio (CLYM) Assets Average (2021 - 2026) Analysis & Trends
Climb Bio (CLYM) has 6 years of Assets Average data on file, last reported at $160.1 million in Q1 2026.
- Quarterly Assets Average fell 23.4% year-over-year to $160.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $160.1 million (down 23.4% YoY) and the FY2025 annual result came in at $192.5 million, up 17.48% from the prior year.
- Assets Average slipped to $160.1 million in Q1 2026, from $175.0 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $224.1 million in Q3 2024 to a low of $109.9 million in Q1 2024.
- A 5-year average of $160.6 million and a median of $160.1 million in 2026 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average dropped 23.73% — and 2024, when it jumped 96.85%.
- Tracing CLYM's Assets Average over 5 years: stood at $137.9 million in 2022, then slipped by 19.09% to $111.6 million in 2023, then jumped by 96.85% to $219.7 million in 2024, then slipped by 20.33% to $175.0 million in 2025, then declined by 8.55% to $160.1 million in 2026.
- The last three Assets Average figures came in at $160.1 million (Q1 2026), $175.0 million (Q4 2025), and $187.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 199.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 199.33 Mn |
| Mar 31, 2026 | 160.06 Mn |
| Dec 31, 2025 | 175.02 Mn |
| Sep 30, 2025 | 187.35 Mn |
| Jun 30, 2025 | 196.56 Mn |
| Mar 31, 2025 | 208.96 Mn |
| Dec 31, 2024 | 219.69 Mn |
| Sep 30, 2024 | 224.11 Mn |
| Jun 30, 2024 | 167.68 Mn |
| Mar 31, 2024 | 109.90 Mn |
| Dec 31, 2023 | 111.60 Mn |
| Sep 30, 2023 | 114.50 Mn |
| Jun 30, 2023 | 119.18 Mn |
| Mar 31, 2023 | 128.54 Mn |
| Dec 31, 2022 | 137.93 Mn |
| Sep 30, 2022 | 145.48 Mn |
| Jun 30, 2022 | 156.26 Mn |
| Mar 31, 2022 | 167.83 Mn |
| Dec 31, 2021 | 177.75 Mn |
| Sep 30, 2021 | 144.94 Mn |